NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
8/100
Mechanism of Action
HIV-1 antiretroviral agent [see Microbiology ()].
Indications (4)
human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistanceintoleranceHIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistancesafety considerations
Loss of Exclusivity
LOE Date
Jul 13, 2029
40 months away
Patent Expiry
Jul 13, 2029